Company
Leap Therapeutics
Also known as Leap Therapeutics, Inc.
- Business model
- B2B
- Legal name
- Leap Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Leap is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 protein.
Funding snapshot
- Total raised
- $105MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $77.2M2023-01-17
Funding rounds
- Round, 2023
- $77.2M2023-01-17, SEC form D sold, 121 investors
- Round, 2017
- $18M2017-11-14, SEC form D sold, 14 investors
- Round, 2011
- $9.9M2011-01-03, SEC form D sold, 4 investors
Loading relationship preview